A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

  1. Laubach, J.P.
  2. Moslehi, J.J.
  3. Francis, S.A.
  4. San Miguel, J.F.
  5. Sonneveld, P.
  6. Orlowski, R.Z.
  7. Moreau, P.
  8. Rosiñol, L.
  9. Faber, E.A.
  10. Voorhees, P.
  11. Mateos, M.-V.
  12. Marquez, L.
  13. Feng, H.
  14. Desai, A.
  15. van de Velde, H.
  16. Elliott, J.
  17. Shi, H.
  18. Dow, E.
  19. Jobanputra, N.
  20. Esseltine, D.-L.
  21. Niculescu, L.
  22. Anderson, K.C.
  23. Lonial, S.
  24. Richardson, P.G.
Aldizkaria:
British Journal of Haematology

ISSN: 1365-2141,  0007-1048

Argitalpen urtea: 2017

Alea: 178

Zenbakia: 4

Orrialdeak: 547-560

Mota: Artikulua

DOI: 10.1111/BJH.14708 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus